SHP099 is a selective and orally bioavailable small-molecule SHP2 inhibitor with IC50 of 0.071 μM.

GSK2830371 is an orally active, allosteric inhibitor of Wip1 phosphatase with IC50 of 6 nM.

Ceramide is a potent modulator of cell proliferation and differentiation.

BTdCPU is acts as an inhibitor of the formation of the ternary complex of eukaryotic translation initiation factor 2 (eIF2), GTP and the initiator methionine tRNA (Met-tRNAi), a key regulatory step of translation initiation.

SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively.

MSX-127 is a potent phosphatase inhibitor.

CCT007093 is an effective PPM1D inhibitor with IC50 of 8.4 μM, that selectively reduces viability of human tumour cell lines.

(-)-p-Bromotetramisole Oxalate is a potent and non-specific alkaline phosphatase inhibitor.

Raphin1 was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington's disease. In cells, Raphin1 caused a rapid and transient accumulation of its phosphorylated substrate, resulting in a transient attenuation of protein synthesis. In vitro, Raphin1 inhibits the recombinant R15B-PP1c holoenzyme, but not the closely related R15A-PP1c, by interfering with substrate recruitment.

Raphin1 Acetate is a selective, R15B inhibitor which caused a rapid and transient accumulation of its phosphorylated substrate like eIF2α, resulting in a transient attenuation of protein synthesis in cells. Raphin1 was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington’s disease.

PTP1B-IN-2 is inhibitor of phosphatase 1B (PTP1B) inhibitor with IC50 of 50 nM.

LB-100 is a small-molecular protein phosphatase 2A (PP2A) inhibitor with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.